- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03499171
Citalopram for Reflux Hypersensitivity and Functional Heartburn
December 4, 2019 updated by: Prof Dr Jan Tack, Universitaire Ziekenhuizen KU Leuven
A Placebo-controlled Trial With Citalopram for the Treatment of Typical Reflux Symptoms in Patients With Reflux Hypersensitivity or Functional Heartburn With Incomplete Proton Pump Inhibitor Response
Citalopram is a drug used in the treatment of depressive episodes and belongs to the group of selective serotonin reuptake inhibitors (SSRI).
Serotonin is an important neurotransmitter predominantly found in the brain and the gastrointestinal tract.
Serotonin is associated with psychological disorders, including anxiety and depression, and emotion regulation and it has been shown that anxiety and depression are associated with increased severity of GERD-related symptoms.
Citalopram and other SSRI's elevate the concentration of serotonin by blocking the reabsorption into the presynaptic neuron and thereby increasing the level of serotonin available to bind the postsynaptic receptor.
A recent study showed beneficial effects of citalopram in patients with reflux hypersensitivity.
However, there was no objective measurement for reflux nor esophageal sensitivity during the treatment period.
Moreover, the effect of citalopram in patients with functional heartburn has not been studied so far.
Therefore, the inevestigators will conduct a randomized, parallel, placebo-controlled study to evaluate the efficacy of citalopram on the improvement in symptom severity, reflux parameters and esophageal sensitivity.
50 patients with reflux hypersensitivity and 50 patients with functional heartburn will receive either placebo or citalopram (Cipramil®) 20 mg as an add-on for a period of 8 weeks.
Symptom severity will be assessed by a validated reflux questionnaire (ReQuest questionnaire and diaries), reflux parameters by performing a 24 hour impedance-pH monitoring and esophageal sensitivity using the multimodal esophageal stimulation paradigm
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hannelore Geysen
- Phone Number: +32 (0)16 324921
- Email: hannelore.geysen@kuleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- UZ Leuven
-
Contact:
- Hannelore Geysen
- Phone Number: +32 (0)16 324921
- Email: hannelore.geysen@kuleuven.be
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 to 65 years old.
- History of typical GERD symptoms during PPI treatment, at least 3 times per week for 12 weeks.
- Daily intake of PPI treatment 12 weeks prior to inclusion, with at least 8 weeks of b.i.d. therapy (at least 2*20mg of omeprazole or equivalent).
- Sexually active women of child bearing potential participating in the study must use a medically acceptable form of contraception. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception.
- Subjects must be capable of understanding and be willing to provide signed and dated written voluntary informed consent before any protocol-specific screening procedures are performed.
Exclusion Criteria:
- Endoscopic signs of severe erosive esophagitis (≥ grade B, Los Angeles classification) on endoscopy performed during PPI treatment in the 6 months prior to screening.
- Systemic diseases, known to affect esophageal motility.
- Surgery in the thorax or in the upper part of the abdomen (appendectomy and cholecystectomy are allowed).
- QT c>450 ms
- Treatment with SSRI's prior to the start of the study.
- Concomitant use of medications such as: anticholinergics, tricycle antidepressants, baclofen and prokinetics.
- Significant neurological, respiratory, hepatic, renal, hematological, cardiovascular, metabolic or gastrointestinal cerebrovascular disease as judged by the investigator.
- Major psychiatric disorder.
- Absence of PPI intake for at least 2 consecutive days in the 2 weeks prior to the screening.
- Pregnancy or breast feeding.
- History of poor compliance. History of/or current psychiatric illness that would interfere with ability to comply with protocol requirements or give informed consent.
- History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Citalopram
20mg, once a day
|
Citalopram is taken once a day as an add-on to PPI treatment (2x/d).
|
Placebo Comparator: Placebo
Once a day
|
Placebo is taken once a day as an add-on to PPI treatment (2x/d)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in number of reflux episodes
Time Frame: 8 weeks
|
The primary efficacy endpoint will be the change in number of reflux episodes assessed by 24 hour impedance-pH monitoring.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in reflux parameters
Time Frame: 8 weeks
|
change in reflux parameters (number of reflux episodes with a high proximal extent, volume exposure) assessed by 24 hour impedance-pH monitoring,
|
8 weeks
|
change in esophageal sensitivity
Time Frame: 8 weeks
|
change in esophageal sensitivity assessed by multimodal esophageal stimulation procedure
|
8 weeks
|
change in symptom severity
Time Frame: 8 weeks
|
change in symptom severity assessed by validated reflux questionnaires (ReQuest questionnaire and diaries).
Patients will have to indicate the symptom occurence and symptom severity on a scale.
Two words, on each site of the scale indicate their symptom severity (on the left "totally not present" on the right "very strong present").
A higher score represents a worse outcome.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 27, 2019
Primary Completion (Anticipated)
April 1, 2021
Study Completion (Anticipated)
April 1, 2021
Study Registration Dates
First Submitted
April 11, 2018
First Submitted That Met QC Criteria
April 11, 2018
First Posted (Actual)
April 17, 2018
Study Record Updates
Last Update Posted (Actual)
December 5, 2019
Last Update Submitted That Met QC Criteria
December 4, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Signs and Symptoms, Digestive
- Hypersensitivity
- Heartburn
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Citalopram
Other Study ID Numbers
- S61111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GERD
-
Baylor Research InstituteNot yet recruiting
-
Ohio State UniversityCompleted
-
EndoStim Inc.TerminatedGERDDenmark, Netherlands, Germany, Austria, United Kingdom, Argentina, Mexico
-
Chong Kun Dang PharmaceuticalCompleted
-
Chong Kun Dang PharmaceuticalCompletedGERDKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedGERDKorea, Republic of
-
Yooyoung Pharmaceutical Co., Ltd.Completed
-
Chong Kun Dang PharmaceuticalCompletedGERDKorea, Republic of
-
Dr. Reddy's Laboratories LimitedCompleted
Clinical Trials on Citalopram 20mg
-
Onconic Therapeutics Inc.CompletedHealthyKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...TerminatedFunctional Chest PainNetherlands
-
University of OxfordRecruiting
-
University of MichiganNational Institute on Aging (NIA)Active, not recruitingParkinson DiseaseUnited States
-
Ciusss de L'Est de l'Île de MontréalCompletedMajor Depressive DisorderCanada
-
University of IowaMayo Clinic; National Institute of Neurological Disorders and Stroke (NINDS); University of Rochester and other collaboratorsCompletedHuntington Disease | Chorea | Executive DysfunctionUnited States
-
Anji PharmaCovanceCompletedFunctional ConstipationChina, United States
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityCompleted
-
Medicines for Malaria VentureQ-Pharm Pty LimitedTerminatedMalaria, FalciparumAustralia